2022
Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaseline
2013
Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV, . Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care 2013, 36: 4030-4035. PMID: 24130350, PMCID: PMC3836135, DOI: 10.2337/dc13-1074.Peer-Reviewed Original ResearchConceptsUsual care groupC-peptide concentrationsType 1 diabetesΒ-cell functionHybrid closed-loop controlSAP therapyPump therapyContinuous glucose monitorNew-onset type 1 diabetesPeak C-peptide concentrationMixed-meal tolerance testSensor-augmented pump therapyEarly intensive therapyΒ-cell preservationUsual care participantsDays of diagnosisC-peptide areaMultiple daily injectionsInsulin pump therapyDays/weekMean glucose concentrationMedian durationIntensive therapyPrimary outcomeDaily injections
2012
The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care 2012, 35: 690-692. PMID: 22374642, PMCID: PMC3308292, DOI: 10.2337/dc11-0732.Peer-Reviewed Original ResearchConceptsType 1 diabetesDetemir insulinInsulin analoguesInsulin pharmacodynamicsRapid-acting insulin analoguesRapid-acting insulinTime-action profileEuglycemic glucose clampCommon regimenRandomized studyDaily injectionsUnits/Glucose clampInsulin actionSame syringePharmacodynamicsAspartInsulinDiabetesRandom orderAdverse effectsSeparate injectionsAction studiesInjectionMixed injectionInsulin Therapy in Children and Adolescents
Tamborlane WV, Sikes KA. Insulin Therapy in Children and Adolescents. Endocrinology And Metabolism Clinics Of North America 2012, 41: 145-160. PMID: 22575411, DOI: 10.1016/j.ecl.2012.01.002.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous insulin infusionInsulin therapyBasal-bolus therapyMainstay of treatmentInsulin replacement therapyType 2 diabetesType 1 diabetesDaily injectionsReplacement therapyAnalogue insulinInsulin infusionInsulin secretionBiosynthetic humanTherapyInsulin formulationsNormal patternDiabetesTreatmentChildrenAdolescentsInfusionAimMainstayInsulin
2010
STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomesEarly Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes
Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010, 33: 1009-1012. PMID: 20150302, PMCID: PMC2858163, DOI: 10.2337/dc09-2118.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose clamp studiesGlucose excursionsClamp studiesMeal-related glucose excursionsRapid-acting insulin analoguesRapid-acting insulinEuglycemic glucose clampTime-action curvePharmacodynamic peakA1c levelsTreatment burdenPharmacodynamic effectsDaily injectionsUnits/Pharmacodynamic actionClinical studiesGlucose clampMixed injectionGlargineEarly pharmacokineticsInsulin analoguesObjective clinicianInsulin pharmacokineticsLispro
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetesInsulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2008, 153: 547-553.e3. PMID: 18589448, DOI: 10.1016/j.jpeds.2008.04.063.Peer-Reviewed Original ResearchConceptsInsulin glargineMultiple daily injectionsMultiple daily injection regimensType 1 diabetes mellitusBaseline A1C valuesDaily insulin glargineParallel group comparisonIntermediate acting insulinIntermediate-acting insulinOccurrence of hypoglycemiaPrandial insulin lisproOverall mean changeElevated A1C.MDI regimenMDI regimensBaseline A1CInjection regimensWeek 24Adverse eventsDiabetes mellitusHemoglobin A1cPediatric patientsSevere hypoglycemiaDaily injectionsA1C values
2005
Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes
Doyle Boland EA, Steffen AT, Tamborlane WV. Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes. The Science Of Diabetes Self-Management And Care 2005, 31: 584-590. PMID: 16100334, DOI: 10.1177/0145721705278888.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesGlycemic controlCSII therapyHypoglycemic episodesInsulin bolus dosesHemoglobin A1c levelsPediatric diabetes clinicSevere hypoglycemic episodesInsulin pump therapySubcutaneous insulin infusionYears of ageAge 13 yearsA1c levelsCatheter siteDiabetes clinicBolus dosesPump therapyDaily injectionsIdeal therapyInsulin infusionInsulin injectionsPostprandial hyperglycemiaFood intakePump use
2004
Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report
Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report. Pediatrics 2004, 114: 1601-1605. PMID: 15574621, DOI: 10.1542/peds.2004-0092.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesMultiple daily injectionsSubcutaneous insulin infusionSevere hypoglycemiaDaily injectionsInsulin infusionRate of SHMonths of CSIIYoung childrenEpisodes of DKAOlder pediatric patientsVery Young ChildrenPersistence of benefitHypoglycemia frequencyYounger patientsGlycemic controlPediatric patientsPump treatmentClinic databaseSafety dataEmergency treatmentAge groupsType 1DiabetesA Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine
Doyle (Boland) E, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine. Diabetes Care 2004, 27: 1554-1558. PMID: 15220227, DOI: 10.2337/diacare.27.7.1554.Peer-Reviewed Original ResearchConceptsTotal daily insulin doseMultiple daily injectionsType 1 diabetesWeeks of therapyGlargine groupDaily injectionsInsulin aspartMDI treatmentShort-term studiesContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseDaily insulin doseSelf-monitored blood glucose measurementsInsulin infusion therapySubcutaneous insulin infusionBlood glucose readingsSelf-monitored blood glucose readingsBlood glucose measurementsDaily glargineCSII groupDose titrationProspective trialAdverse events